Ardelyx, Inc. Investigation
Company: Ardelyx, Inc.
Ticker: (NASDAQ) ARDX
How to Check Whether You May Be Eligible in the Ardelyx, Inc. Investigation
Investigation Details
Ardelyx shares dropped 17.86% on August 7, 2026, closing at $4.00, after the Company cut its full-year 2026 IBSRELA revenue guidance to $350-$370 million from $410-$430 million.
The $410-$430 million IBSRELA range had been reiterated on the Company's Q1 2026 earnings call on April 30, 2026. On August 6, 2026, after the close, Ardelyx reduced the range by approximately $60 million at the midpoint, citing increased payer utilization-management processes -- additional step edits and more stringent prior authorizations -- that slowed new-patient starts. Management stated on the call that the extent of the payer restrictions "was not something that one would anticipate."
In the same release, Ardelyx withdrew its long-term $750 million revenue target for XPHOZAH. Q2 2026 product revenue was $118.1 million with EPS of approximately $(0.07). The investigation concerns whether Ardelyx may not have adequately disclosed the payer dynamics affecting IBSRELA.